David Combarel

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Palliative Care

Epidermal Growth Factor Receptor

Drug Administration

Metastatic Renal Cell Carcinoma

Top Venues

Clinical pharmacology and therapeutics

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Arthur Geraud, David Combarel, Christian Funck-Brentano, Quentin Beaulieu, Noël Zahr, Sophie Broutin, Jean-Philippe Spano, Christophe Massard, Benjamin Besse, Paul Gougis
A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer. Clinical pharmacology and therapeutics (2024)
Francesco Facchinetti, Yohann Loriot, Floriane Braye, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice Andre, Ken A Olaussen, Antoine Hollebecque, Luc Friboulet
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Arthur Geraud, David Combarel, Christian Funck-Brentano, Quentin Beaulieu, Noël Zahr, Sophie Broutin, Jean-Philippe Spano, Christophe Massard, Benjamin Besse, Paul Gougis
A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer. Clinical pharmacology and therapeutics 116 (3) (2024)
David Combarel, Arthur Geraud, Paul Gougis
Reply to: "Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer" and "Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails". Clinical pharmacology and therapeutics (2024)
David Combarel, Arthur Geraud, Paul Gougis
Reply to: "Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer" and "Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails". Clinical pharmacology and therapeutics 116 (3) (2024)
Francesco Facchinetti, Antoine Hollebecque, Floriane Braye, Damien Vasseur, Yoann Pradat, Rastislav Bahleda, Cedric Pobel, Ludovic Bigot, Olivier Deas, Juan David Florez Arango, Giorgia Guaitoli, Hayato Mizuta, David Combarel, Lambros Tselikas, Stefan Michiels, Sergey I Nikolaev, Jean Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Ken A Olaussen, Yohann Loriot, Luc Friboulet
Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer. Cancer discovery (2023)